Strovolos – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 20 Aug 2026 12:31:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Strovolos – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Improving Quality of Life for Early Breast Cancer Patients Using Duloxetine and Furosemide to Manage Endocrine Therapy-Related Pain https://clinicaltrials.eu/trial/study-on-improving-quality-of-life-for-early-breast-cancer-patients-using-duloxetine-and-furosemide-to-manage-endocrine-therapy-related-pain/ Mon, 03 Aug 2026 10:33:38 +0000 https://clinicaltrials.eu/trial/study-on-improving-quality-of-life-for-early-breast-cancer-patients-using-duloxetine-and-furosemide-to-manage-endocrine-therapy-related-pain/ This clinical trial is focused on improving the quality of life for patients with early-stage breast cancer who are experiencing symptoms related to their endocrine therapy. The study is specifically looking at patients with ER-positive HER2-negative breast cancer in stages I-II. The trial will explore the effectiveness of two medications, duloxetine and furosemide, in managing pain associated with endocrine therapy, such as joint pain, muscle pain, and bone pain.

The purpose of the study is to determine if either duloxetine or furosemide can better control these types of pain over a period of three months. Participants will be randomly assigned to receive one of these medications or a placebo. The study will last for up to six months, during which participants will take the medication orally. The trial aims to assess changes in pain levels and overall quality of life using specific questionnaires designed to measure these aspects.

Throughout the study, participants will be monitored for any changes in their symptoms and overall health. The trial will also evaluate the safety of the medications by tracking any side effects or adverse events. The ultimate goal is to find supportive treatments that can help patients manage the side effects of their cancer therapy, thereby improving their quality of life during treatment.

]]> Study on the Safety of Tiragolumab and Atezolizumab for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-on-the-safety-of-tiragolumab-and-atezolizumab-for-patients-with-advanced-or-metastatic-solid-tumors/ Mon, 03 Aug 2026 10:25:39 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-tiragolumab-and-atezolizumab-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying the safety and behavior of a new treatment for people with certain types of cancer known as solid tumors. These tumors can be locally advanced, which means they have grown but not spread far, or they can be recurrent, meaning they have come back after treatment, or metastatic, which means they have spread to other parts of the body. The treatment being tested is a combination of two medications, atezolizumab and tiragolumab, given together as a solution through an intravenous infusion, which is a way to deliver medicine directly into the bloodstream.

The purpose of this study is to evaluate how safe this combination treatment is and how it behaves in the body. Participants will receive the treatment and be monitored for any side effects or reactions. The study will also look at how the body processes the medications, including how much of the drug is present in the blood at different times. This will help researchers understand the treatment’s safety and how it might work in treating solid tumors.

Throughout the study, participants will receive regular check-ups and tests to monitor their health and the effects of the treatment. The study aims to gather important information that could lead to new treatment options for people with solid tumors. The trial is expected to continue until late 2025, providing valuable insights into the potential benefits and risks of this new treatment combination.

]]> Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma https://clinicaltrials.eu/trial/study-on-the-effect-of-chemotherapy-with-ifosfamide-dacarbazine-and-epirubicin-hydrochloride-before-surgery-for-patients-with-high-risk-retroperitoneal-sarcoma/ Mon, 03 Aug 2026 10:08:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-chemotherapy-with-ifosfamide-dacarbazine-and-epirubicin-hydrochloride-before-surgery-for-patients-with-high-risk-retroperitoneal-sarcoma/ This clinical trial is focused on studying the effects of chemotherapy before surgery in patients with a type of cancer called retroperitoneal sarcoma. This cancer occurs in the area behind the abdominal organs. The study specifically looks at two subtypes of this cancer: leiomyosarcoma and liposarcoma. The treatment being tested involves using chemotherapy drugs such as ifosfamide, dacarbazine, epirubicin hydrochloride, and doxorubicin hydrochloride. These drugs are given through a vein, which is known as intravenous use.

The purpose of the study is to see if giving chemotherapy before surgery can improve the chances of the cancer not coming back after surgery. Patients will be randomly assigned to receive either chemotherapy followed by surgery or surgery alone. The study will last for several years, and patients will be monitored for their health and any signs of cancer returning. The main focus is on how long patients remain free of cancer after treatment, which is called disease-free survival. Other aspects being studied include overall survival, the response of the cancer to the chemotherapy, and any side effects from the treatment.

Participants in the study will undergo various tests and procedures, including imaging tests like MRI and CT scans, to assess the size and spread of the cancer. These tests help doctors determine if the cancer can be surgically removed. The study aims to gather information that could help improve treatment strategies for patients with high-risk retroperitoneal sarcoma, potentially leading to better outcomes and quality of life.

]]> Bank Of Cyprus Oncology Center https://clinicaltrials.eu/site/bank-of-cyprus-oncology-center/ Tue, 12 May 2026 06:10:36 +0000 https://clinicaltrials.eu/site/bank-of-cyprus-oncology-center-3/ Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse https://clinicaltrials.eu/trial/study-on-elacestrant-for-treating-er-her2-breast-cancer-in-patients-with-ctdna-relapse/ Wed, 29 Apr 2026 14:26:11 +0000 https://clinicaltrials.eu/trial/study-on-elacestrant-for-treating-er-her2-breast-cancer-in-patients-with-ctdna-relapse/ This clinical trial is focused on studying the treatment of breast cancer, specifically in patients who have a type of breast cancer known as ER+/HER2-. This means the cancer cells have receptors for estrogen but not for a protein called HER2. The study is investigating a medication called elacestrant, which is being compared to standard endocrine therapy. Endocrine therapy is a treatment that blocks or lowers the amount of hormones in the body to slow down or stop the growth of cancer. The purpose of the study is to see if elacestrant can delay the spread of cancer to other parts of the body or prevent death in patients who have a relapse detected by a test called ctDNA, which looks for cancer DNA in the blood.

Participants in the study will be randomly assigned to receive either elacestrant or one of the standard endocrine therapies, which include medications like tamoxifen, anastrozole, exemestane, and letrozole. Some patients may also receive additional treatments such as leuprorelin, goserelin, or triptorelin, which are used to lower hormone levels in the body. The study will last for a period of up to 104 weeks, during which the effects of the treatments will be monitored. The study aims to determine which treatment is more effective in preventing the cancer from spreading or causing death.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the progress of the treatment. These tests may include imaging scans like MRI or CT scans, which use magnetic fields or X-rays to create detailed pictures of the inside of the body. The study will also collect information on the safety of the treatments and how they affect the quality of life of the participants. The results of this study could help improve treatment options for patients with this type of breast cancer in the future.

]]>